Conference Reports for NATAP

Back

The International Liver Congress™ EASL - European Association for the Study of the Liver 2019 April 10-14 Vienna Austria     Prevalence of hepatitis C virus infection among men who have sex with men in Moscow - (06/03/20)   Effectiveness of therapy in 16,567 directly-acting antiviral treated people in England: high response rates in genotype 3 hepatitis C infection regardless of degree of fibrosis, but ribavirin improves response in cirrhosis - (07/08/19)   Antigen suppression effect of the core protein allosteric modulator RO7049389 in AAV-HBV mice is accompanied by transient upregulation of immune-cell gene signatures in the liver - (06/12/19)   A first-in-class orally available HBV cccDNAdestabilizer ccc_R08 achieved sustainable HBsAg and cccDNA reduction in the HBVcircle mouse model - (06/12/19)   RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients - (06/12/19)   In vitro and in vivo antiviral characterization of RO7049389, a novel small molecule capsid assembly modulator, for the treatment of chronic hepatitis B - (06/05/19)   RO7049389, a core protein allosteric modulator, demonstrates robust decline in HBV DNA and HBV RNA in chronic HBV infected patients - (06/05/19)   EDP-514, a Novel HBV Core Inhibitor with Potent Antiviral Activity both In Vitro and In Vivo - (06/05/19)   Genotype 3 patients treated with glecaprevir/pibrentasvir: Real world outcomes from an unselected cohort - (05/30/19)   High efficacy of SOF+VEL regardless of patients' clinical characteristics - (05/30/19)   Prospective Evaluation of Serum Alkaline Phosphatase Variability and Prognostic Utility in Primary Sclerosing Cholangitis Using Controlled Clinical Trial Data - (05/28/19)   Validation of Histologic and Noninvasive Measures of Fibrosis as Surrogate Endpoints of Disease Progression in Patients with Primary Sclerosing Cholangitis - (05/28/19)   The hepatitis C cascade of care and treatment outcomes among people who inject drugs in a Norwegian low-threshold setting: A real life experience - (05/21/19)   Access to Direct Acting Antiviral Agents in HIV/HCV Co-Infected Population in the US - (05/16/19)   CANCER RISK AMONG PEOPLE WITH HIV, HBV AND/OR HCV INFECTIONS - (05/16/19)   Iceland may already have reached the WHO 2030 targets for diagnosis and treatment of hepatitis C virus infection. Results from the Treatment as Prevention for Hepatitis C (TrapHepC) program - (05/14/19)   Incidence and predictors of flares after discontinuing nucleos(t)ide analogue therapy in HBeAg negative patients with chronic hepatitis B: Results from the randomized controlled STOP Study - (05/13/19)   Uptake of testing and treatment for HCV among PWID in Australia: The ETHOS Engage Study - "59% HCV treatment uptake" - (05/13/19)   Is it possible to successfully link migrants to HBV, HCV and HIV services upon arrival in the European Union? - (05/13/19)   Is homelessness the biggest hurdle to treatment success in the management of HCV in the era of direct acting antivirals? - Results from the TraP HepC nationwide treatment initiative in Iceland - - (05/13/19)   Factors associated with hepatitis C treatment uptake among people who inject drugs in a population based data linkage study Next Steps - (05/13/19)   THE PRIORITIZE STUDY: A Pragmatic, Randomized Study of Oral Regimens for Hepatitis C: Transforming Decision-Making for Patients, Providers, and Stakeholders - (05/09/19)   EASL 2019 HCV Highlights Report: Treatment, Retreatment, Elimination, Fatty Liver/HIV, Resistance Testing, Reinfection - (05/09/19)   NGM313, a Novel Activator of β-Klotho/FGFR1c: A Single Dose Significantly Reduces Steatosis (Liver Fat by MRI-PDFF), Inflammation (ALT, AST) and FibrogenicActivity (Pro-C3) in NAFLD Subjects - (05/08/19)   Merck (Fatty Liver Disease/NASH) and NGM Bio Announce Extension of Broad, Multi-Year Strategic Collaboration to 2022 - (05/08/19)   New Non-Invasive NASH/Fibrosis Biomarkers - A Comparative Study of Fibrosis Treatments using Aptamer-Based Quantitative Proteomics in a Model of Nonalcoholic Steatohepatitis Cirrhosis - (05/08/19)   A Novel Approach to Funding HCV and HBV Treatment for all -Uzbekistan Pilot Project - (05/08/19)   The short and long term impact of scaling up treatment for hepatitis B and C on disease burden - (05/08/19)   A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/08/19)   MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/08/19)   A comparison of currently available direct acting antiviral HCV therapy in Canada - On the path to elimination - (05/07/19)   HCV treatment outcomes among current and remote people who inject drugs (PWID): real life data - (05/07/19)   MR elastography based fibrosis correlates with clinical liver events in patients with non-alcoholic fatty liver disease: A multi-center study - (05/07/19)   Liver enzymes cut offs in patients with advanced non-alcoholic fatty liver disease: A multi-center study - (05/07/19)   A Simple Algorithm Based on Electronic Medical Records to Identify NAFLD with Advanced Fibrosis in Patients with Type 2 Diabetes - (05/07/19)   The natural history of NASH-induced advanced fibrosis in a large cohort of patients with type-2 diabetes - (05/07/19)   Rwanda HCV Elimination Project - (05/07/19)   New in France: Universal Access for HCV-treatment as demonstrated by a nationwide real-world cohort - (05/07/19)   Insulin resistance is a cause of steatosis and fibrosis progression in chronic hepatitis C - (05/07/19)   The combination of HEPAmet fibrosis score and transient elastography shows a high diagnostic accuracy in predicting advanced fibrosis in NAFLD - (05/07/19)   Resistance-guided retreatment of HCV infected patients with a previous failure to an NS5A inhibitor-containing regimen: Italian real life experience - (04/30/19)   Food, Obesity and Non-Alcoholic Fatty Liver Disease (NAFLD) - (04/30/19)   LIFESTYLE FOR THE TREATMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE - (04/30/19)   CONTRA Testing for HCV RASs after DAA Failure and Choices of Retreatment - (04/30/19)   4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC) - (04/30/19)   Phase 1a Study of the Safety, Tolerability and Pharmacokinetics of ABI-H2158, a Novel Second-Generation HBV Core Inhibitor, In Healthy Volunteers - (04/29/19)   Rapid Turnover of HBV cccDNA in Chronic Hepatitis B Patients During Drug Resistance Emergence and Breakthrough - (04/29/19)   Safety, Antiviral Activity, and Pharmacokinetics of a Novel Hepatitis B Virus Capsid Assembly Modulator, JNJ-56136379, in Asian and Caucasian Patients with Chronic Hepatitis B - (04/29/19)   A Phase 1, Double-Blind, Randomised, Placebo-Controlled, First-in-Human Study of the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of oral JNJ-64794964, a Toll-like Receptor-7 Agonist, in Healthy Adults - (04/29/19)   JNJ-64530440, a Novel Capsid Assembly Modulator: Single- and Multiple-Ascending Dose Safety, Tolerability and Pharmacokinetics in Healthy Volunteers - (04/29/19)   Sequence Analysis of Baseline and On-treatment Samples from HBV-infected Chronic Hepatitis B Patients Treated for 28 Days with JNJ-56136379 Monotherapy - (04/29/19)   HBcrAg Decline in JNJ-56136379-treated Chronic Hepatitis B Patients: Results of a Phase 1 Study - (04/29/19)   Comparison of HCV resistance-associated substitutions in patients infected with HCV genotype 3 before and after failure to DAA combination therapies - (04/26/19)   EVALUATION OF HEPATITIS C VIRUS RAPID DIAGNOSTIC TESTS IN HCV MONO- AND HCV/HIV CO-INFECTED PATIENTS FROM LOW- AND MIDDLE-INCOME COUNTRIES - (04/26/19)   PRO: Testing for HCV Resistance-Associated Variants (RAVs) in Patients After DAA Failure and Impact on Subsequent Drug Selection - (04/26/19)   The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)   The socio-economic burden of NASH in Europe and the United States: the GAIN study - (04/26/19)   A diet based on high-heat-treated foods promotes risk factors for diabetes mellitus and cardiovascular diseases - (04/23/19)   High red and processed meat consumption is associated with non-alcoholic fatty liver disease and insulin resistance - (04/23/19)   Liver Disease in UK General Population: Fatty & Alcohol Liver Disease; Lack of Awareness: 4% aware; High Rate of Risk Factors: 89% - (04/23/19)   Evaluation of HBV Outcomes After Treatment Discontinuation From 4 Phase 3 Studies - (04/23/19)   A Phase 3 Study Comparing Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide With Continued TDF Treatment in Virologically Suppressed Patients With Chronic Hepatitis B: Week 48 Efficacy and Safety Results - (04/23/19)   EVALUATION OF HEPATITIS C VIRUS RAPID DIAGNOSTIC TESTS IN HCV MONO- AND HCV/HIV CO-INFECTED PATIENTS FROM LOW- AND MIDDLE-INCOME COUNTRIES - (04/23/19)   EASL Wrap-up session: Metabolic and alcohol related liver disease, Fatty Liver/NASH - (04/23/19)   Incidence of hepatocellular carcinoma and mortality after HCV elimination by all-oral DAA therapy: Results from a large-scale, multicenter [older age] cohort study - (04/22/19)   Efficacy and safety of Glecaprevir/Pibrentasvir in patients with severe renal impairment in Japan: a prospective, multicenter study (KTK 49 Liver Study Group) - (04/22/19)   Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy - (04/22/19)   Efficacy and Safety of glecaprevir/pibrentasvir for the Pangenotypic Treatment of Chronic Hepatitis C in former intravenous drug users: Subanalysis from a Spanish Real-World Cohort (Hepa-C) - (04/22/19)   Shortened duration pan-genotypic therapy with glecaprevir-pibrentasvirfor six weeks among people with acute and recent HCV infection - (04/22/19)   4 week treatment [G/P+/-Rbv] for hepatitis C - a randomized controlled trial (4RIBC) - (04/22/19)   Prospective Multicenter Study of Glecaprevir + Pibrentasvir Combination Therapy for Patients with Chronic Hepatitis C - (04/22/19)   Real-life effectiveness and safety of Glecaprevir/Pibrentasvir in HCV-infected patients with chronic kidney disease - (04/22/19)   An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir/grazoprevir treatment association for chronic hepatitis C in France : No effect of alcohol consumption or dependence on treatment outcome - (04/22/19)   An observational study on comorbidities and comedication patterns in chronic hepatitis C patients treated with second generation direct acting antivirals (DAA) in Belgium (FRI-221) - (04/22/19)   Increasing Number of Metabolic Co-Morbidities are Associated with Higher Risk of Advanced Fibrosis in Patients with Nonalcoholic Steatohepatitis - (04/22/19)   A Combination of the ACC Inhibitor GS-0976 (firsocostat) and the Nonsteroidal FXR Agonist GS-9674 (cilofexor) Improves Hepatic Steatosis, Biochemistry, and Stiffness in Patients With Nonalcoholic Steatohepatitis - (04/22/19)   APPLICATION OF GUIDELINES FOR FATTY LIVER IN TWO PROSPECTIVE COHORTS OF HIV+ PATIENTS: 32% have NAFLD; among those without NAFLD 18% with elevated ALT - (04/22/19)   Effect of treatment of hepatitis B patients with tenofovir disoproxilor entecaviron risk of hepatocellular cancer and death in a U.S. cohort - (04/19/19)   Preclinical Profile of HBV Core Protein Inhibitor, ABI-H3733, a Potent Inhibitor of cccDNA Generation in HBV Infected Cells - (04/19/19)   Antiviral activity of JNJ-4964 (AL-034/TQ-A3334),a selective Toll-Like Receptor 7 agonist, after oral administration for 12 weeks in AAV/HBV mice - (04/19/19)   Short term RNA interference (RNAi) therapy in chronic hepatitis B (CHB) using JNJ-3989 brings majority of patients to HBsAg <100 IU/ml threshold - (04/19/19)   Interim Safety and Efficacy Results of the ABI-H0731 Phase 2a Program Exploring the Combination of ABI-H0731 with Nuc Therapy in Treatment-Naive and Treatment-Suppressed Chronic Hepatitis B Patients - (04/19/19)   Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B - (04/19/19)   Increasing incidence of HCV-GT2 and reinfections within the ongoing epidemic of acute HCV infections among MSM in Central Europe - (04/18/19)   The impact of SVR from direct acting antiviral and interferon-based treatments for HCV on hepatocellular carcinoma risk in a large population based cohort - (04/18/19)   Ramucirumab for Patients with Advanced Hepatocellular Carcinoma and Elevated Alpha-Fetoprotein Following Sorafenib: Outcomes by Liver Disease Aetiology from Two Randomised, Placebo-Controlled Phase 3 Studies (REACH-2 And REACH) - (04/18/19)   Unacceptably low SVR rates in African patients with unusual HCV sub-genotypes: Implications for global elimination - (04/18/19)   Best of ILC 2019 Viral hepatitis - (04/18/19)   Simplified monitoring for hepatitis C virus treatment with glecaprevir plus pibrentasvir: the SMART-C study - (04/18/19)   The Increasing Importance of Non-alcoholic Fatty Liver Disease (NAFLD) in Patients with Human Immunodeficiency Virus (HIV) - (04/18/19)   HCV RE-INFECTION AMONG HIV-INFECTED MSM IN NEW YORK CITY - (04/17/19)   The global investment case for hepatitis C elimination - (04/17/19)   EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR IN PATIENTS WITH HEPATITIS C VIRUS GENOTYPE 1 INFECTION WHO RECEIVE OPIOID AGONIST THERAPY: TREATMENT UTILIZATION AND THE IMPACT OF CONCOMITANT PSYCHIATRIC MEDICATIONS - (04/17/19)   Real world effectiveness and utilization patterns of Elbasvir/Grazoprevir for treatment of HCV G1 G4 infected patients in Italy - (04/17/19)   Hepatitis C virus reinfection following antiviral treatment among people who inject drugs: A systematic review and meta-analysis - (04/15/19)   Reinfection following successful HCV DAA therapy among people with recent injecting drug use - (04/15/19)   HIGH REAL-WORLD EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) IN PWID ON OPIOID SUBSTITUTION THERAPY WITH HCV GENOTYPE 1 (GT1) INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)   HIGH EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) TREATMENT IN PATIENTS WITH HCV GENOTYPE 1A (GT1A) INFECTION IN GERMAN REAL-WORLD: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)   HIGH REAL-WORLD EFFECTIVENESS OF ELBASVIR/GRAZOPREVIR (EBR/GZR) IN A HCV GENOTYPE 1 (GT1) POPULATION WITH A MIGRATION BACKGROUND AND PREDOMINANT SUBTYPE 1B INFECTION: RESULTS FROM THE GERMAN HEPATITIS C REGISTRY (DHC-R) - (04/15/19)   Effectiveness of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Genotype 1 Infection Receiving Dialysis - (04/15/19)   Safety and Efficacy of Glecaprevir/Pibrentasvir for the Treatment of HCV Genotype 1-6: Results of the HCV-TARGET Study - (04/15/19)   Immediate versus delayed hepatitis C treatment in the United Kingdom: A pan-genotypic cost-effectiveness analysis - (04/15/19)   HCV Elimination Off-Track WHO Targets/Countries Estimates - Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - (04/15/19)   Achieving accelerated elimination of hepatitis C virus infection by 2025: a case study in France - (04/15/19)   Global timing of hepatitis C virus elimination: estimating the year countries will achieve the World Health Organization elimination targets - (04/15/19)   REAL-WORLD EFFECTIVENESS AND SAFETY OF GLECAPREVIR/PIBRENTASVIR IN ADULTS WITH CHRONIC HEPATITIS C VIRUS INFECTION: A META-ANALYSIS - (04/15/19)   Real-World Health Care Resource Utilizati on and Quality of Life With Glecaprevir/Pibrentasvir Treatment: A Pooled Analysis From Post-Marketing Observational Studies - (04/13/19)   High Efficacy and Improvement in CPT Class With Sofosbuvir/Velpatasvir Plus Ribavirin for 12 Weeks in Patients With CPT C Decompensated Cirrhosis - (04/13/19)   Clinical and virological characteristics of patients with chronic hepatitis C and failure to a Voxilaprevir (VOX)/Velpatasvir (VEL)/Sofosbuvir (SOF) treatment - (04/13/19)   Treatment of genotype 3 cirrhotic patients with 12 weeks of Sofosbuvir/Velpatasvir with or without Ribavirin: Real life experience from Italy - (04/13/19)   EFFECTIVENESS AND SAFETY OF SOFOSBUVIR/VELPATASVIR/VOXILAPREVIR FOR RETREATMENT OF CHRONIC HEPATITIS C PATIENTS WITH A PREVIOUS FAILURE TO DIRECT-ACTING ANTIVIRALS: A REAL-LIFE STUDY FROM THE NAVIGATORE LOMBARDIA AND VENETO NETWORKS - (04/13/19)   High cure rates of Hepatitis C in a genotype 3 predominant Pakistani community using generic direct acting antivirals - (04/13/19)   REAL-WORLD SAFETY, EFFECTIVENESS, AND PATIENT-REPORTED OUTCOMES IN PATIENTS WITH CHRONIC HEPATITIS C VIRUS INFECTION TREATED WITH GLECAPREVIR/PIBRENTASVIR: DATA FROM THE GERMAN HEPATITIS C-REGISTRY - (04/13/19)   Efficacy and Safety of Glecaprevir/Pibrentasvir in Patients With HCV Genotype 5 or 6 Infection: An Integrated Analysis of Phase 2 and 3 Studies - (04/13/19)   Sofosbuvir + Velpatasvir + Voxilaprevir in DAA Failure Patients with Cirrhosis Final Results of the French Compassionate Use Program - (04/13/19)   Efficacy and Safety of Glecaprevir/Pibrentasvir Treatment for 8 Weeks in Treatment-Naïve Patients With Chronic Hepatitis C Virus Infection Without Cirrhosis or With Compensated Cirrhosis: Analysis of Data Pooled From Phase 2 and 3 Studies - (04/13/19)   Patient Flow Across Physician Specialties Over the Course of the Hepatitis C Care Cascade: A Real-World Analysis From the United States - (04/13/19)   Positive Results from REGENERATE: A Phase 3 International, Randomized, Placebo-Controlled Study Evaluating Obeticholic Acid Treatment for NASH - (04/13/19)   HIV-infected individuals at high risk of non-alcoholic fatty liver disease (NAFLD) and progressive liver disease- ILC 2019: Latest studies confirm increasing burden of NAFLD in people with HIV infection as viral hepatitis prevalence and associated mortality decline - (04/12/19)   Clinical practice experience with pangenotypic therapies glecaprevir/pibrentasvir and sofosbuvir/velpatasvir; data from the TRIO Network - (04/12/19)   Retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and prior DAA failure - an analysis from the German Hepatitis C-Registry (DHC-R) - (04/12/19)   Global real world evidence of sofosbuvir/velpatasvir as a simple, effective regimen for the treatment of chronic hepatitis C: Integrated analysis of 12 clinical practice cohorts - (04/12/19)   Real-World Effectiveness and Safety of Glecaprevir Plus Pibrentasvir in HCV: A Multi -Country Analysis of Post-Marketing Observational Studies - (04/12/19)   Effectiveness of the salvage therapy sofosbuvir/velpatasvir/voxilaprevir (SOF/VEL/VOX) in chronic hepatitis C; clinical practice experience from the TRIO network - (04/12/19)